首页|用于胶质母细胞瘤治疗的siRNA非病毒递送系统研究进展

用于胶质母细胞瘤治疗的siRNA非病毒递送系统研究进展

扫码查看
胶质母细胞瘤(GBM)是恶性程度较高的脑部肿瘤,具有高致残率、高复发率的特点.GBM经常规治疗后易复发,且耐药患者预后情况不佳.小干扰RNA(siRNA)能通过沉默特定基因、下调蛋白表达而产生疗效,可作为常规治疗的补充,进一步抑制GBM的发展进程.文章阐述了 siRNA递送入脑的困境、siRNA治疗GBM的作用机制,并总结了 5种用于 GBM治疗的siRNA非病毒递送系统,以期为siRNA在GBM治疗中的应用研究提供参考.
Research Progress on Non-viral Delivery Systems of siRNA for Glioblastoma Treatment
Glioblastoma(GBM)is a highly malignant brain tumor with high disability and recurrence rate.Conventional treatment for GBM is prone to recurrence,and the prognosis of drug-resistant patients is unfavorable.Small interfering RNA(siRNA)can generate therapeutic effects by silencing specific genes and down-regulating protein expression,and can serve as a supplement to conventional treatment by inhibiting the development process of GBM.This review elaborates on the difficulties of siRNA delivery into the brain and the mechanism of GBM treatment by siRNA.Additionally,it summarizes the application of five non-viral siRNA delivery systems for GBM treatment,in order to provide a reference for the application research of siRNA in GBM treatment.

glioblastomasiRNAlipid nanoparticleliposomepolymeric nanoparticlemicelleexosomeresearch progress

江芷萱、贾瑞沂、丁源、陆伟跃

展开 >

复旦大学药学院药剂学系,智能化递药教育部及全军 重点实验室(复旦大学),上海 201203

上海泰禛生物技术有限公司研发部,上海 201314

胶质母细胞瘤 siRNA 脂质纳米粒 脂质体 聚合物纳米粒 胶束 外泌体 研究进展

2024

中国医药工业杂志
上海医药工业研究院,中国化学制药工业协会

中国医药工业杂志

CSTPCD
影响因子:0.487
ISSN:1001-8255
年,卷(期):2024.55(10)